Italia markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
92,42-0,56 (-0,60%)
In data: 02:54PM EDT. Mercato aperto.

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
https://www.biontech.de

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno6.133

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Ugur Sahin M.D.Co-Founder, CEO & Chair of the Management Board1,25MN/D1965
Dr. Ozlem Tureci M.D.Co-Founder, Chief Medical Officer & Member of Management Board822,13kN/D1967
Mr. Jens H. HolsteinCFO & Member of Management Board1,44MN/D1963
Dr. Sierk Poetting Ph.D.MD, COO & Member of Management Board844,88kN/D1973
Mr. Ryan RichardsonChief Strategy Officer, MD & Member of Management Board1,04MN/D1979
Mr. Sean MarettChief Business Officer, Chief Commercial Officer & Member of Management Board815,63kN/D1965
Dr. James Timothy Patrick Ryan Ph.D.Chief Legal Officer & Member of the Management Board610,91kN/D1975
Mr. Zach TaylorSenior Vice President of Corporate Development & StrategyN/DN/DN/D
Dr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesN/DN/DN/D
Dr. Oliver Henning Ph.D.Senior Vice President of OperationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Governance aziendale

L'ISS Governance QualityScore di BioNTech SE al 1 marzo 2024 è 5. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.